HHS proposed changes that would roll back many Biden-era policies, eliminate most health tech certification criteria,and ...

Northwell Holdings — the venture capital arm of Northwell Health, the largest health system in New York state — says it is focused on making investments in innovative companies that improve patient ...

Venture capital funding for healthcare IT companies — those selling enterprise software to providers and payers — is slowly picking back up after its low point in the fourth quarter of 2022, according ...

In a Friday letter, a group of pharmacy organizations called on Congressional leadership to take action on pharmacy benefit manager reform. The organizations included in the letter are the National ...

Thyme Care, a value-based cancer care company, has secured $95 million in Series C funding, which it will use to grow its business, the company announced Tuesday. Nashville, Tennessee-based Thyme Care ...

Deloitte’s 2026 Healthcare Outlook shows that while more than two-thirds of U.S. healthcare leaders expect to outperform competitors, rising policy uncertainty is pushing greater focus on digital care ...

Omeros’s complement system drug Yartemlea is now FDA approved for treating a severe and potentially fatal complication of hematopoietic stem cell transplants. Our recap of other regulatory actions ...

This week, Dexcom became the first medical device company to integrate generative AI into a continuous glucose monitor. The company added generative AI to its Stelo glucose monitor, which it began ...

More than 50 major insurers have pledged to streamline prior authorization starting in 2026, but providers remain cautiously optimistic and skeptical that the changes will truly reduce burden or ...

Medicare Part D spending on 10 diabetes drugs reached $35.8 billion in 2023, a 364% increase from 2019 at $7.7 billion, according to a February report from the Office of Inspector General (OIG). At ...

The Centers for Medicare and Medicaid Services aims to have all Medicare beneficiaries in a value-based arrangement by 2030. But achieving that will be a difficult undertaking, with just 12% of ...

Eli Lilly showed a drug that goes after two metabolic targets to treat obesity can successfully shed weight and become a revenue-generating heavyweight. Other companies aspire to improve on the Lilly ...